EUROPACE 2009 EUROPACE, the official congress of the European Heart Rhythm Association (EHRA), is today the foremost European meeting on cardiac arrhythmias and pacing. More than 4,000 participants are expected to attend this year's event, whose two main themes are atrial fibrillation and sudden cardiac death. EHRA is a registered branch of the European Society of Cardiology (ESC). Its mission is to reduce the impact of cardiac arrhythmias and sudden cardiac death (SCD).
Source: www.medicalnewstoday.comCardiogenesis Announces Successful Educational Symposium At Society Of Thoracic Surgeons Meeting In San Francisco Cardiogenesis Corporation (Pink Sheets: CGCP), a global leader of innovative therapies for ischemic cardiac disease and the market leader of surgical products for transmyocardial revascularization (TMR), sponsored an educational symposium titled "Advancements in Revascularization & Stem Cell Therapy," which was attended by over 40 cardiothoracic surgeons. The Program Chair was Dr. Emerson Perin, Director, New Interventional Cardiovascular Technology, Texas Heart Institute.
Source: www.medicalnewstoday.comWinners Of 2009 Student Travel Awards Announced By The Biophysical Society The Biophysical Society has announced the winners of its student travel award to attend the Biophysical Society's 53rd Annual Meeting at the Boston Convention and Exhibition Center in Boston, Massachusetts, February 28-March 4, 2009. The recipients of this competitive award are selected based on scientific merit, with priority given to those who will present a paper at the conference.
Source: www.medicalnewstoday.comFrost & Sullivan To Host Analyst Briefing On The European Orphan Diseases Market: Niche-Busters - An Attractive Future? The Healthcare Group at Frost & Sullivan is pleased to announce its 2009 Quarterly Analyst Briefing Presentation on the European Orphan Diseases Market to be held on Thursday, 5 February, 2009 at 2 p.m. GMT. Today's pharmaceutical companies are facing a tough competition in the generics market because of the patent expiry of blockbuster molecules. CEOs have had to re-think and take alternative options to maintain the growth of the organization and to satisfy the stakeholders.
Source: www.medicalnewstoday.comVarian Medical Systems And BrainLAB To Showcase Novalis Tx(TM) Platform For Non Invasive Image Guided Radiosurgery A new non-invasive surgical device for eradicating inoperable lung cancer and other conditions is being showcased this week at the 45th Annual Society of Thoracic Surgeons (STS) Meeting in San Francisco. The Novalis Tx(TM) platform from Varian Medical Systems (NYSE: VAR) and BrainLAB enables doctors to perform image-guided radiosurgery on tumors of the lung, as well as of the brain, spine, liver, and prostate, without making a single incision.
Source: www.medicalnewstoday.com
# posted by Network @ 11:32 AM
